Therapeutic Drug Monitoring of Rivastigmine and Donepezil Under Consideration of CYP2D6 Genotype-Dependent Metabolism of Donepezil

References

• NICE. Dementia: A NICE-SCIE Guideline on Supporting People with Dementia and Their Carers in Health and Social Care. Leicester, London: British Psychological Society; Royal College of Psychiatrists; 2007.
   Google Scholar
• DeuschlG, WeaM. S3-Leitlinie Demenzen; 2016 Available from:www.dgn.org/leitlinien. Accessed 912, 2017.
   Google Scholar
• GauthierS, PattersonC, ChertkowH, et al. 4th Canadian Consensus Conference on the Diagnosis and Treatment of Dementia. Can J Neurol Sci. 2012;39(6 Suppl 5):S1–S8. doi:10.1017/s0317167100015183
   PubMed Web of Science ®Google Scholar
• Guideline Adaption Committee. Clinical Practice Guidelines and Principles of Care for People with Dementia. Sydney; 2016.
   Google Scholar
• DoodyRS, StevensJC, BeckC, et al. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56(9):1154–1166. doi:10.1212/WNL.56.9.115411342679
   PubMed Web of Science ®Google Scholar
• ChouM-C, ChenC-H, LiuC-K, ChenS-H, WuS-J, YangY-H. Concentrations of rivastigmine and NAP 226-90 and the cognitive response in Taiwanese Alzheimer’s disease patients. J Alzheimers Dis. 2012;31(4):857–864. doi:10.3233/JAD-2012-12010922751168
   PubMed Web of Science ®Google Scholar
• ChenT-H, ChouM-C, LaiC-L, WuS-J, HsuC-L, YangY-H. Factors affecting therapeutic response to rivastigmine in Alzheimer’s disease patients in Taiwan. Kaohsiung J Med Sci. 2017;33(6):277–283. doi:10.1016/j.kjms.2017.04.00628601231
   PubMed Web of Science ®Google Scholar
• RogersSL, DoodyRS, MohsRC, FriedhoffLT. Donepezil improves cognition and global function in Alzheimer disease. A 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med. 1998a;158(9):1021–1031. doi:10.1001/archinte.158.9.10219588436
   PubMed Web of Science ®Google Scholar
• YangY-H, ChenC-H, ChouM-C, LiC-H, LiuC-K, ChenS-H. Concentration of donepezil to the cognitive response in Alzheimer disease. J Clin Psychopharmacol. 2013;33(3):351–355. doi:10.1097/JCP.0b013e31828b508723609381
   PubMed Web of Science ®Google Scholar
• LuJ, WanL, ZhongY, et al. Stereoselective metabolism of donepezil and steady-state plasma concentrations of S-donepezil based on CYP2D6 polymorphisms in the therapeutic responses of Han Chinese patients with Alzheimer’s disease. J Pharmacol Sci. 2015;129(3):188–195. doi:10.1016/j.jphs.2015.10.01026603528
   PubMed Web of Science ®Google Scholar
• MirandaLFJR, GomesKB, TitoPAL, et al. Clinical response to donepezil in mild and moderate dementia. relationship to drug plasma concentration and CYP2D6 and APOE genetic polymorphisms. J Alzheimers Dis. 2017;55(2):539–549. doi:10.3233/JAD-16016427716659
   PubMed Web of Science ®Google Scholar
• HefnerG, BruecknerA, HiemkeC, FellgiebelA. Therapeutic drug monitoring for patients with Alzheimer Dementia to improve treatment with donepezil. Ther Drug Monit. 2015;37(3):353–361. doi:10.1097/FTD.000000000000015225384119
   PubMed Web of Science ®Google Scholar
• GobburuJV, TammaraV, LeskoL, et al. Pharmacokinetic-pharmacodynamic modeling of rivastigmine, a cholinesterase inhibitor, in patients with Alzheimer’s disease. J Clin Pharmacol. 2001;41(10):1082–1090. doi:10.1177/0091270012201268911583476
   PubMed Web of Science ®Google Scholar
• VarsaldiF, MiglioG, ScordoMG, et al. Impact of the CYP2D6 polymorphism on steady-state plasma concentrations and clinical outcome of donepezil in Alzheimer’s disease patients. Eur J Clin Pharmacol. 2006;62(9):721–726. doi:10.1007/s00228-006-0168-116845507
   PubMed Web of Science ®Google Scholar
• FDA. NDA 22-083/S016 Exelon® Patch (rivastigmine transdermal system). Available from:https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022083orig1s016.pdf. Accessed 820, 2017.
   Google Scholar
• MeyerUA, ZangerUM. Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu Rev Pharmacol Toxicol. 1997;37:269–296. doi:10.1146/annurev.pharmtox.37.1.2699131254
   PubMed Web of Science ®Google Scholar
• SachseC, BrockmöllerJ, BauerS, RootsI. Cytochrome P450 2D6 variants in a Caucasian population. Allele frequencies and phenotypic consequences. Am J Hum Genet. 1997;60(2):284–295.9012401
   PubMed Web of Science ®Google Scholar
• RaimundoS, ToscanoC, KleinK, et al. A novel intronic mutation, 2988GA, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects. Clin Pharmacol Ther. 2004;76(2):128–138. doi:10.1016/j.clpt.2004.04.00915289790
   PubMed Web of Science ®Google Scholar
• HicksJK, SwenJJ, ThornCF, et al. Clinical pharmacogenetics implementation consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin Pharmacol Ther. 2013;93(5):402–408. doi:10.1038/clpt.2013.223486447
   PubMed Web of Science ®Google Scholar
• NoetzliM, GuidiM, EbbingK, et al. Population pharmacokinetic approach to evaluate the effect of CYP2D6, CYP3A, ABCB1, POR and NR1I2 genotypes on donepezil clearance. Br J Clin Pharmacol. 2014;78(1):135–144. doi:10.1111/bcp.1232524433464
   PubMed Web of Science ®Google Scholar
• MagliuloL, DahlM-L, LombardiG, et al. Do CYP3A and ABCB1 genotypes influence the plasma concentration and clinical outcome of donepezil treatment? Eur J Clin Pharmacol. 2011;67(1):47–54. doi:10.1007/s00228-010-0883-520931330
   PubMed Web of Science ®Google Scholar
• CacabelosR. Donepezil in Alzheimer’s disease. From conventional trials to pharmacogenetics. Neuropsychiatr Dis Treat. 2007;3(3):303–333.19300564
   PubMedGoogle Scholar
• SteimerW, ZöpfK, von AmelunxenS, et al. Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers. Clin Chem. 2004;50(9):1623–1633. doi:10.1373/clinchem.2003.03082515205367
   PubMed Web of Science ®Google Scholar
• GonzalezFJ, SkodaRC, KimuraS, et al. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature. 1988;331(6155):442–446. doi:10.1038/331442a03123997
   PubMed Web of Science ®Google Scholar
• FDA. Aricept label information. Available from:https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020690s039,021720s012,022568s008lbl.pdf. Accessed 821, 2017.
   Google Scholar
• MoriE, IkedaM, NakaiK, MiyagishiH, NakagawaM, KosakaK. Increased plasma donepezil concentration improves cognitive function in patients with dementia with Lewy bodies. An exploratory pharmacokinetic/pharmacodynamic analysis in a Phase 3 randomized controlled trial. J Neurol Sci. 2016;366:184–190. doi:10.1016/j.jns.2016.05.00127288803
   PubMed Web of Science ®Google Scholar
• BullockR, BergmanH, TouchonJ, et al. Effect of age on response to rivastigmine or donepezil in patients with Alzheimer’s disease. Curr Med Res Opin. 2006;22(3):483–494. doi:10.1185/030079906X8968516574032
   PubMed Web of Science ®Google Scholar
• CoinA, PamioMV, AlexopoulosC, et al. Donepezil plasma concentrations, CYP2D6 and CYP3A4 phenotypes, and cognitive outcome in Alzheimer’s disease. Eur J Clin Pharmacol. 2016;72(6):711–717. doi:10.1007/s00228-016-2033-126952092
   PubMed Web of Science ®Google Scholar
• SonaliN, TripathiM, SagarR, VelpandianT, SubbiahV. Impact of CYP2D6 and CYP3A4 genetic polymorphism on combined cholinesterase inhibitors and memantine treatment in mild to moderate Alzheimer’s disease. Dement Geriatr Cogn Disord. 2014;37(1–2):58–70. doi:10.1159/00035005024107805
   PubMed Web of Science ®Google Scholar
• SeripaD, BizzarroA, PilottoA, et al. Role of cytochrome P4502D6 functional polymorphisms in the efficacy of donepezil in patients with Alzheimer’s disease. Pharmacogenet Genomics. 2011;21(4):225–230. doi:10.1097/FPC.0b013e32833f984c20859244
   PubMed Web of Science ®Google Scholar
• OrtnerM, StangeM, SchneiderH, et al. Serum concentrations of cholinesterase inhibitors in patients with Alzheimer’s dementia are frequently below the recommended levels. Front Pharmacol. 2020;11:691. doi:10.3389/fphar.2020.0069132508640
   PubMed Web of Science ®Google Scholar
• OrtnerM, KurzA, AlexopoulosP, et al. Small vessel disease, but neither amyloid load nor metabolic deficit, is dependent on age at onset in Alzheimer’s disease. Biol Psychiatry. 2015;77(8):704–710. doi:10.1016/j.biopsych.2014.01.01924613195
   PubMed Web of Science ®Google Scholar
• FolsteinMF, FolsteinSE, McHughPR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189–198. doi:10.1016/0022-3956(75)90026-61202204
   PubMed Web of Science ®Google Scholar
• MorrisJC, HeymanA, MohsRC, et al. The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer’s disease. Neurology. 1989;39(9):1159–1165. doi:10.1212/WNL.39.9.11592771064
   PubMed Web of Science ®Google Scholar
• WatsonYI, ArfkenCL, BirgeSJ. Clock completion. An objective screening test for dementia. J Am Geriatr Soc. 1993;41(11):1235–1240. doi:10.1111/j.1532-5415.1993.tb07308.x8227899
   PubMed Web of Science ®Google Scholar
• McKhannGM, KnopmanDS, ChertkowH, et al. The diagnosis of dementia due to Alzheimer’s disease. Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):263–269. doi:10.1016/j.jalz.2011.03.00521514250
   PubMed Web of Science ®Google Scholar
• WelshK, ButtersN, HughesJ, MohsR, HeymanA. Detection of abnormal memory decline in mild cases of Alzheimer’s disease using CERAD neuropsychological measures. Arch Neurol. 1991;48(3):278–281. doi:10.1001/archneur.1991.005301500460162001185
   PubMedGoogle Scholar
• LuY, QinX, LiS, et al. Quantitative assessment of CYP2D6 polymorphisms and risk of Alzheimer’s disease: a meta-analysis. J Neurol Sci. 2014;343(1–2):15–22. doi:10.1016/j.jns.2014.05.03324909950
   PubMed Web of Science ®Google Scholar
• RogersSL, FriedhoffLT. Pharmacokinetic and pharmacodynamic profile of donepezil HCl following single oral doses. Br J Clin Pharmacol. 1998;46(Suppl 1):1–6. doi:10.1046/j.1365-2125.1998.0460s1001.x
   PubMed Web of Science ®Google Scholar
• HiemkeC, BergemannN, ClementHW, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry. 2018;51(1–02):9–62. doi:10.1055/s-0043-11649228910830
   PubMed Web of Science ®Google Scholar
• KoeberR, Kluenemann-H-H, WaimerR, et al. Implementation of a cost-effective HPLC/UV-approach for medical routine quantification of donepezil in human serum. J Chromatogr B Analyt Technol Biomed Life Sci. 2012;881–882:1–11. doi:10.1016/j.jchromb.2011.10.027
   PubMed Web of Science ®Google Scholar
• LefèvreG, SedekG, JheeSS, et al. Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer’s disease patients. Clin Pharmacol Ther. 2008;83(1):106–114. doi:10.1038/sj.clpt.610024217522596
   PubMed Web of Science ®Google Scholar
• ChouW-H, YanF-X, Robbins-WeilertDK, et al. Comparison of two CYP2D6 genotyping methods and assessment of genotype-phenotype relationships. Clin Chem. 2003;49(4):542–551. doi:10.1373/49.4.54212651805
   PubMed Web of Science ®Google Scholar
• GrieseEU, ZangerUM, BrudermannsU, et al. Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics. 1998;8(1):15–26. doi:10.1097/00008571-199802000-000039511177
   PubMedGoogle Scholar
• DahlML, JohanssonI, BertilssonL, Ingelman-SundbergM, SjöqvistF. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J Pharmacol Exp Ther. 1995;274(1):516–520.7616439
   PubMed Web of Science ®Google Scholar
• ZangerUM, FischerJ, RaimundoS, et al. Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. Pharmacogenetics. 2001;11(7):573–585. doi:10.1097/00008571-200110000-0000411668217
   PubMedGoogle Scholar